SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the appointment of Lyn Wiesinger to its Board of Directors. Her career has encompassed leadership roles at Pfizer, Rhone-Poulenc Rorer, Bristol-Myers Squibb and Vicuron Pharmaceuticals.
